AI Set to Accelerate Drug Research and Development for Aging Population
TL/DR –
AI has the potential to significantly expedite drug research and development for the biopharma industry by increasing efficiency, reducing costs and success rates. This can be particularly beneficial for treatments for diseases like Alzheimer’s, with AI projected to reduce discovery timelines by about 3 years, early-stage R&D costs by 25-60%, and preclinical timelines by 30-50%. However, the success of AI in drug development still needs to be proven in Phase 2 and beyond, with its potential to increase drug approvals by 10 to 40% yet to be seen.
AI’s Potential to Speed Up Drug Research for Aging Population
Artificial Intelligence (AI) holds significant potential for the biopharma industry, particularly in terms of improvement in efficiency, cost savings, and success rates. This is especially true for researching treatments for age-related diseases like Alzheimer’s. New drug development often involves a tedious, costly process that takes 10-15 years and up to $2.8 billion, with only about a 10% success rate.
AI can target these inefficiencies directly, revolutionizing drug development by transforming it from a trial-and-error method to a data-driven system. It aids in better target selection, efficient molecule design, and smarter clinical trial execution, boosting the chances of higher-probability candidates. Sean Laaman, head of U.S. SMID Cap Biotech Research, suggests that AI can reduce discovery timelines by around three years, cut early-stage R&D costs by about 25-60%, and shorten preclinical timelines by approximately 30-50%. He also points to early evidence of improved Phase 1-2 success rates. However, it remains to be seen whether AI can also translate into success in Phase 2 and beyond.
If AI can indeed improve timelines and success rates, it “has the potential to increase drug approvals by 10 to 40%”, according to U.S. Biopharma Analyst Terence Flynn. This comes at a time when approximately $160 billion in revenue across U.S. large-cap biopharma companies is expected to go off patent before 2030, presenting new challenges for companies’ R&D, investor, and growth strategies.
The role of AI in the industry is also evident in the M&A activity across multiple sectors. John Collins and Tom Miles, Global Heads of M&A at Morgan Stanley, noted that AI investment continues to shape M&A activity, with acquirers actively targeting AI-enabled capabilities to boost productivity, speed up innovation, and build competitive advantages. Biotech acquisitions by pharmaceutical companies featured prominently in these M&A activities, as they aim to refill their drug pipelines. According to a recent M&A report, healthcare transactions accounted for 11% of M&A volume in the first half of 2026.
—
Read More Health & Wellness News ; US News